Development of a new tacaribe arenavirus infection model and its use to explore antiviral activity of a novel aristeromycin analog

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-11

  Gowen, Brian B ^a   Wong, Min Hui ^a   Larson, Deanna ^a   Ye, Wei ^b   Jung, Kie Hoon ^a   Sefing, Eric J ^a   Skirpstunas, Ramona ^a,c   Smee, Donald F ^a   Morrey, John D ^a   Schneller, Stewart W ^b  

^a UTAH STATE UNIVERSITY   (United States)

^b AUBURN UNIVERSITY   (United States)

^c Department of Agriculture and Food ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' HOMOARISTEROMYCIN; ALPHA BETA INTERFERON RECEPTOR; ANTIVIRUS AGENT; GAMMA INTERFERON RECEPTOR; MY 24; NEUTRALIZING ANTIBODY; PLACEBO; RIBAVIRIN; UNCLASSIFIED DRUG; ADENOSINE; ARISTEROMYCIN; DRUG DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARENAVIRUS INFECTION; ARTICLE; BLOOD; BRAIN; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG STRUCTURE; FEMALE; IMMUNE RESPONSE; LIVER; LOW DRUG DOSE; MALE; MORTALITY; MOUSE; NONHUMAN; SPLEEN; SYRIAN HAMSTER; VIRUS INHIBITION; VIRUS PATHOGENESIS; VIRUS REPLICATION; ANIMAL; ARENAVIRUS; CERCOPITHECUS; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; HAMSTER; HUMAN; MOUSE MUTANT; PHYSIOLOGY; VERO CELL; VIROLOGY;

ANIMALIA; ARENAVIRUS; CRICETINAE; MUS; NEW WORLD ARENAVIRUSES; PICHINDE VIRUS; TACARIBE VIRUS;

ADENOSINE; ANIMALS; ANTIVIRAL AGENTS; ARENAVIRIDAE INFECTIONS; ARENAVIRUSES, NEW WORLD; CERCOPITHECUS AETHIOPS; CRICETINAE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MESOCRICETUS; MICE; MICE, KNOCKOUT; VERO CELLS; VIRUS REPLICATION;

EID: 77958577192     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012760     Document Type: Article

References (42)

1. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, et al. (2002) Hemorrhagic fever viruses as biological weapons: medical and public health management. Jama 287: 2391-2405.
2. Delgado S, Erickson BR, Agudo R, Blair PJ, Vallejo E, et al. (2008) Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. PLoS Pathog 4: e1000047.
3. Gowen BB, Holbrook MR (2008) Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses. Antiviral Res 78: 79-90.
4. Bolken TC, Laquerre S, Zhang Y, Bailey TR, Pevear DC, et al. (2006) Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res 69: 86-97.
5. Martinez-Sobrido L, Giannakas P, Cubitt B, Garcia-Sastre A, de la Torre JC (2007) Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J Virol 81: 12696-12703.
6. Grajkowski A, Pedras-Vasconcelos J, Wang V, Ausin C, Hess S, et al. (2005) Thermolytic CpG-containing DNA oligonucleotides as potential immunotherapeutic prodrugs. Nucleic Acids Res 33: 3550-3560.
7. van den Broek MF, Muller U, Huang S, Aguet M, Zinkernagel RM (1995) Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. Journal of Virology 69: 4792-4796.
8. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E (2006) Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 80: 10208-10217.
9. Ryman KD, Meier KC, Gardner CL, Adegboyega PA, Klimstra WB (2007) Non-pathogenic Sindbis virus causes hemorrhagic fever in the absence of alpha/ beta and gamma interferons. Virology 368: 273-285.
10. Maiztegui JI, Fernandez NJ, de Damilano AJ (1979) Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 2: 1216-1217.
11. Enria DA, Briggiler AM, Levis S, Vallejos D, Maiztegui JI, et al. (1987) Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever. Antiviral Res 7: 353-359.
12. Enria DA, Briggiler AM, Sanchez Z (2008) Treatment of Argentine hemorrhagic fever. Antiviral Res 78: 132-139.
13. Kilgore PE, Ksiazek TG, Rollin PE, Mills JN, Villagra MR, et al. (1997) Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clinical Infectious Diseases 24: 718-722.
14. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, et al. (1986) Lassa fever. Effective therapy with ribavirin. New England Journal of Medicine 314: 20-26.
15. Leyssen P, De Clercq E, Neyts J (2008) Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res 78: 9-25.
16. Snell NJ (2001) Ribavirin-current status of a broad spectrum antiviral agent. Expert Opinion on Pharmacotherapy 2: 1317-1324.
17. Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, et al. (2007) In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 51: 3168-3176.
18. Gowen BB, Smee DF, Wong MH, Hall JO, Jung KH, et al. (2008) Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One 3: e3725.
19. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, et al. (2005) Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49: 981-986.
20. Peters CJ, Liu CT, Anderson GW Jr., Morrill JC, Jahrling PB (1989) Pathogenesis of viral hemorrhagic fevers: Rift Valley fever and Lassa fever contrasted. Reviews of Infectious Diseases 11 Suppl 4: S743-749.
21. Asper M, Sternsdorf T, Hass M, Drosten C, Rhode A, et al. (2004) Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus. Journal of Virology 78: 3162-3169.
22. Gowen BB, Barnard DL, Smee DF, Wong MH, Pace AM, et al. (2005) Interferon alfacon-1 protects hamsters from lethal pichinde virus infection. Antimicrob Agents Chemother 49: 2378-2386.
23. Gowen BB, Smee DF, Wong MH, Pace AM, Jung KH, et al. (2006) Combinatorial ribavirin and interferon alfacon-1 therapy of acute arenaviral disease in hamsters. Antivir Chem Chemother 17: 175-183.
24. Soares MM, King SW, Thorpe PE (2008) Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat Med 14: 1357-1362.
25. Schneller SW (2002) Carbocyclic nucleosides (carbanucleosides) as new therapeutic leads. Curr Top Med Chem 2: 1087-1092.
26. Rodriguez JB, Comin MJ (2003) New progresses in the enantioselective synthesis and biological properties of carbocyclic nucleosides. Mini Rev Med Chem 3: 95-114.
27. Kishi T, Muroi M, Kusaka T, Nishikawa M, Kamiya K, et al. (1972) Structure of aristeromycin. Chemical and Pharmaceutical Bulletin 20: 940-946.
28. De Clercq E (2005) John Montgomery's legacy: carbocyclic adenosine analogues as SAH hydrolase inhibitors with broad-spectrum antiviral activity. Nucleosides Nucleotides Nucleic Acids 24: 1395-1415.
29. Cools M, De Clercq E (1990) Influence of S-adenosylhomocysteine hydrolase inhibitors on S-adenosylhomocysteine and S-adenosylmethionine pool levels in L929 cells. Biochem Pharmacol 40: 2259-2264.
30. Bennett LL Jr., Allan PW, Rose LM, Comber RN, Secrist JA 3rd (1986) Differences in the metabolism and metabolic effects of the carbocyclic adenosine analogs, neplanocin A and aristeromycin. Mol Pharmacol 29: 383-390.
31. Bennett LL Jr., Bowdon BJ, Allan PW, Rose LM (1986) Evidence that the carbocyclic analog of adenosine has different mechanisms of cytotoxicity to cells with adenosine kinase activity and to cells lacking this enzyme. Biochem Pharmacol 35: 4106-4109.
32. Bennett LL Jr., Brockman RW, Rose LM, Allan PW, Shaddix SC, et al. (1985) Inhibition of utilization of hypoxanthine and guanine in cells treated with the carbocyclic analog of adenosine. Phosphates of carbocyclic nucleoside analogs as inhibitors of hypoxanthine (guanine) phosphoribosyltransferase. Mol Pharmacol 27: 666-675.
33. Hill DL, Straight S, Allan PW, Bennett LL Jr. (1971) Inhibition of guanine metabolism of mammalian tumor cells by the carbocyclic analogue of adenosine. Mol Pharmacol 7: 375-380.
34. Yang M, Schneller SW (2005) 59-Homoaristeromycin. Synthesis and antiviral activity against orthopox viruses. Bioorg Med Chem Lett 15: 149-151.
35. Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. American Journal of Hygiene 27: 493-497.
36. Montgomery JA, Clayton SJ, Thomas HJ, Shannon WM, Arnett G, et al. (1982) Carbocyclic analogue of 3-deazaadenosine: a novel antiviral agent using Sadenosylhomocysteine hydrolase as a pharmacological target. J Med Chem 25: 626-629.
37. Xiao SY, Zhang H, Yang Y, Tesh RB (2001) Pirital virus (Arenaviridae) infection in the syrian golden hamster, Mesocricetus auratus: a new animal model for arenaviral hemorrhagic fever. American Journal of Tropical Medicine and Hygiene 64: 111-118.
38. Hall WC, Geisbert TW, Huggins JW, Jahrling PB (1996) Experimental infection of guinea pigs with Venezuelan hemorrhagic fever virus (Guanarito): a model of human disease. Am J Trop Med Hyg 55: 81-88.
39. Jahrling PB, Smith S, Hesse RA, Rhoderick JB (1982) Pathogenesis of Lassa virus infection in guinea pigs. Infect Immun 37: 771-778.
40. Oubina JR, Carballal G, Videla CM, Cossio PM (1984) The guinea pig model for Argentine hemorrhagic fever. Am J Trop Med Hyg 33: 1251-1257.
41. Bray M (2005) Pathogenesis of viral hemorrhagic fever. Current Opinion in Immunology 17: 399-403.
42. Schnittler HJ, Feldmann H (2003) Viral hemorrhagic fever-a vascular disease? Thromb Haemost 89: 967-972.